Of the 164 innovative medicines, which have been since 2019. by 2022. Registered in European Union (EU) countries, and thus the patients in these countries, only 14 of them are available in Bosnia and Herzegovina.
It told us that Ana Petrović, director of the Association of Innovative Medicines Manufacturers in BiH.
– He talks all the time – we’re a little market. Slovenia also has a small market, so the average availability of innovative medications in that country is 72. The European average is 74. I don’t know if BiH annually introduces one new drug. With us from 2019. Not a revised list of drugs of solidarity, and is the main channel of new drugs in our country, because there are therapies for heavy forms of cancer, melanoma, multiple sclerosis, rare diseases, although those as such They were not defined as severe diseases … – says Petrović.
The process of creating a new drug, according to our interlocutor, is extremely difficult and it takes an average of about ten years to prove that it is safe for the patient, writes Factor.
– Therefore, financial investment in medicines are higher. Therefore, there are more and less new medications because it is difficult to finance something for what you ultimately are unsure of being a patient. Remember that in this process of placing the drug is relevant regulatory bodies, such as the US food and medicine agency (FDA) and the European Agency for Medicines (EMA) that must confirm the safety and quality of the patient that further affects his availability of patients. Furthermore, innovative medicine and when it is released into the use of his action is still monitored – said Petrovic.
